Tricyclic dibenzothiazepine type compounds for use in the therapy of cdkl5 disorder

Abstract

Tricyclic dibenzothiazepine compounds for use in the treatment of CDKL5 disorder. Specifically, a compound of Formula I, or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity for use in the treatment of CDKL5 disorder in a mammal, wherein a compound of Formula I comprises: or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, wherein: R1 and R3 each independently represent, at each occurrence when used herein, H or C1 to C5 alkyl; R2 represents halo; R4 and R5 each independently represent H; R6 represents —C(O)OR9; X represents CH2, O or S; R9 represents H or C1 to C5 alkyl; and, m is an integer from 1 to 6 inclusive.

Dependencies are inferred from the claim text.